




PATENT APPLICATION
Docket No: 8747.116

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Larry Rigby)
Serial No.: 10/649,322)
Filed: August 27, 2003)
For: METHODS AND APPARATUS FOR)
TRANSDERMAL DELIVERY OF)
ABUSABLE PAIN MEDICATION WITH)
DETERRENT AGENT)

CERTIFICATE OF DEPOSIT UNDER 37 C.F.R. § 1.8

Thereby certify that this correspondence and the documents listed below are being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on Nov. 20, 2003.


Michael F. Krieger
Attorney for Applicant
Registration No. 35,232

Transmitted: Transmittal for Information Disclosure Statement
Information Disclosure Statement
Form PTO-1449 Listing of All References
Legible Copies of All Listed References
Postcard

MFK:jrr



MICHAEL F. KRIEGER
REGISTERED PATENT ATTORNEY

**KIRTON &
McCONKIE**
A PROFESSIONAL CORPORATION
ATTORNEYS AT LAW
1800 EAGLE GATE TOWER
60 EAST SOUTH TEMPLE
P.O. BOX 45120
SALT LAKE CITY, UTAH 84145-0120
www.kmclaw.com

FAX (801) 321-4893
TELEPHONE (801) 328-3600
E-MAIL: mkrieger@kmclaw.com

PATENT APPLICATION
Docket No: 8747.116

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
TRANSMITTAL FOR INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing and pursuant to 37 C.F.R. § 1.97 is an Information Disclosure Statement. Enclosed also are the following designated documents, as required under 37 C.F.R. §§ 1.97 and 1.98:

- ☒ Form PTO-1449 list of nine (9) references submitted for consideration.
- ☒ Legible copies of the listed references or their relevant portions.
- ☐ All English translations of each nonenglish reference, if any, within the possession, custody, control or availability of anyone designated in 37 C.F.R. § 1.56(c) (see 37 C.F.R. § 1.98(c)).

The following are included within the Information Disclosure Statement if applicable and as required under 37 C.F.R. § 1.98:

- ☐ Concise explanation of relevance of each reference not in English and unaccompanied by an English translation.
- ☐ Statement that certain listed references not enclosed are substantially cumulative of an enclosed reference.

___ Statement that certain listed references not enclosed were previously cited by or submitted to the Office in the identified prior application _____, filed on _____, which is relied upon for an earlier filing date under 35 U.S.C. ' 120.

In order to secure consideration of the items designated above, one or more of the following, if required, is also enclosed:

___ Promptness Certification.


___ Check No. _____ in the amount of \$ _____ constituting submission fee -- see 37 C.F.R. § 1.17(p)

___ Petition for Consideration and Check No. _____ in the amount of \$ _____ -- see 37 C.F.R. § 1.17(i)(1).

X In the event that 37 C.F.R. § 1.97(c) applies and the Examiner is not satisfied that the Promptness Certification meets the requirements of 37 C.F.R. § 1.97(e), or in any other event remediable by a fee, please credit any over payment or charge any additional fees to Deposit Account No. 500843 of the undersigned.

DATED this 20 day of November 2003.

Respectfully submitted,


Michael F. Krieger
Attorney for Applicant
Registration No. 35,232

KIRTON & McCONKIE
1000 Eagle Gate Tower
60 East South Temple
Salt Lake City, Utah 84111
Telephone: (801) 533-9800
Facsimile: (801) 321-1707



PATENT APPLICATION
Docket No: 8747.116

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	Larry Rigby)
)
Serial No.:	10/649,322)
)
Filed:	August 27, 2003)
)
For:	METHODS AND APPARATUS FOR)
	TRANSDERMAL DELIVERY OF)
	ABUSABLE PAIN MEDICATION WITH)
	DETERRENT AGENT)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449 which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). While no representation is made that any of these references may be "prior art" within the meaning of that term under 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record


believes that the enclosed art is the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

In accordance with 37 C.F.R. §§ 1.97 and 1.98, a copy of each of the listed references or relevant portion thereof is also enclosed.

Please credit any over payment or charge any additional fees to Deposit Account No. 500843 of the undersigned.

Dated this 20 day of November, 2003.

Respectfully submitted,


Michael F. Krieger
Attorney for Applicant
Registration No. 35,232

KIRTON & McCONKIE
1800 Eagle Gate Tower
60 East South Temple
Salt Lake City, Utah 84111
Telephone: (801) 328-3600
Facsimile: (801) 328-1707

MFK:jrr



Applicant: Larry Rigby
 Serial No.: 10/649,322
 Filing Date: August 27, 2003
 For:

Att'y Docket No. 8747.116

METHODS AND APPARATUS FOR TRANSDERMAL DELIVERY OF
 ABUSABLE PAIN MEDICATION WITH DETERRENT AGENT

INFORMATION DISCLOSURE CITATIONS MADE BY APPLICANT

U.S. Patent Documents

<u>Examiner Initial*</u>	<u>Document Number</u>	<u>Issue Date</u>	<u>Name</u>	<u>Class</u>	<u>Sub Class</u>	<u>Filing Date</u>
_____ A1.	4,457,933	07/03/84	Gordon et al.	424	260	12/11/81
_____ A2.	5,149,538	09/22/92	Granger et al.	424	449	06/14/91
_____ A3.	5,580,876	12/03/96	Crain et al.	514	282	11/03/95
_____ A4.	6,153,215	11/28/00	Samuelsen et al.	424	448	08/26/93
_____ A5.	6,228,863	05/08/01	Palermo et al.	514	282	12/22/98
_____ A6.	6,277,384	08/21/01	Kaiko et al.	424	400	12/22/98
_____ A7.	6,277,398	08/21/01	Caruso	424	443	11/16/99
_____ A8.	6,306,425	10/23/01	Tice et al.	424	426	04/07/00
_____ A9.	6,375,957	04/23/02	Kaiko et al.	424	400	02/11/00

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Applicant: Larry Rigby
Serial No.: 10/649,322
Filing Date: August 27, 2003
For:

Att'y Docket No. 8747.116

METHODS AND APPARATUS FOR TRANSDERMAL DELIVERY OF
ABUSABLE PAIN MEDICATION WITH DETERRENT AGENT

Prior Art Cited by Applicants

While the filing of prior art statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper prior art statement, Form PTO-1449 shall be accompanied by an explanation of relevance of each listed item, a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all prior art citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as prior art cited by the Examiner on Form PTO-892.

The reference designations "A1", "A2", etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A", "B", "C", etc. on Office Action Form PTO-1142.

::ODMA\PCDOCS\DOCS\720001\1

Examiner:Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
